FDA's ODAC votes unanimously that future PI3K inhibitors should include randomized data for blood cancers - Endpoints News

4/21/2022 12:00:00 AM3 yearsago
by Kyle LaHucik

A panel of FDA's outside advisors unanimously voted, with one abstention, that future approvals of PI3K inhibitors should be supported by randomized data. The 17-member ODAC panel was asked by federal regulators to discuss observed toxicities of the Phosphati…

A pan­el of FDA’s out­side ad­vi­sors unan­i­mous­ly vot­ed, with one ab­sten­tion, that fu­ture ap­provals of PI3K in­hibitors should be sup­port­ed by ran­dom­ized da­ta. The 17-mem­ber ODAC pan­e… [+4971 chars]

full article...